Total
0
Shares
Mayne Pharma Group (ASX:MYX) - Chairman, Roger Corbett - The Market Herald
Chairman, Roger Corbett
Source: Mayne Pharma Group
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Mayne Pharma (MYX) faces a class action over alleged failures to inform investors of an anti-competitive conduct probe by the US Department of Justice and the Office of the Attorney General in the State of Connecticut
  • The class action is brought by Phi Finney McDonald on behalf of investors who bought shares in MYX between November, 2014, and December, 2016
  • The law firm said the class action will allege Mayne’s share price was inflated by failures to disclose information regarding the investigation
  • Mayne Pharma says it will "vigorously defend the proceeding" and "emphatically denies any and all allegations of wrongdoing"
  • Mayne Pharma shares are down 4.48 per cent at 2:08 pm AEST to trade at 32 cents.

Mayne Pharma (MYX) is facing a class action over allegations it failed to disclose to investors an investigation by the US Department of Justice and the Office of the Attorney General in the State of Connecticut into alleged anti-competitive conduct.

The class action has been brought by law firm Phi Finney McDonald on behalf of investors who acquired shares in the US-based pharmaceutical company between November 24, 2014, and December 15, 2016.

Mayne Pharma said it would "vigorously defend the proceeding" which alleges the company "breached its continuous disclosure obligations and engaged in misleading and deceptive conduct".

In an ASX release earlier today, Mayne Pharma said it "emphatically denies any and all allegations of wrongdoing".

According to Phi Finney McDonald, the class action follows an announcement from December 2016 that the Attorney General of Connecticut had commenced anti-trust civil proceedings against a number of pharmaceutical companies, including Mayne Pharma.

Phi Finney McDonald claims Mayne failed to inform investors that it was likely to face civil or criminal action relating to price-fixing and market-sharing arrangements in the US, which were claimed to be in breach of the Sherman Antitrust Act.

The act is designed to prohibit trusts, monopolies and cartels as well as outlaw business practices that restrain trade and create monopolies within industries.

Phi Finney McDonald said the class action would allege that Mayne’s share price was inflated by failures to disclose this information and that shareholders suffered loss and damage.

Mayne Pharma shares were down 4.48 per cent at 2:08 pm AEST to trade at 32 cents.

MYX by the numbers
More From The Market Herald
Vita Group (ASX:VTG) – Chief Executive Officer, Maxine Horne - The Market Herald

" Vita Group (ASX:VTG) sells retail telco business to Telstra (ASX:TLS)

Vita Group (VTG) is planning to sell its retail Information and Communication Technology business to Telstra Corporation (TLS) for $110 million.
The Market Herald Video

" Sandfire Resources (ASX:SFR) to spend $2.57b buying Spanish copper mine

Sandfire Resources (SFR) is planning to raise $1.28 billion in equity to help fund the acquisition of the MATSA Mining Complex in Spain.
Widgie Nickel (ASX:WIN) begins trading on ASX after $24m raise

" Widgie Nickel (ASX:WIN) begins trading on ASX after $24m raise

Widgie Nickel (WIN) has officially commenced trading on the ASX nearly five years after it was removed under its former name.
APA Group (ASX:APA) shares dip amid AusNet Services (ASX:ANV) bidding war

" APA Group (ASX:APA) shares dip amid AusNet Services (ASX:ANV) bidding war

APA Group (APA) shares have dipped after the business announced failed plans to acquire all of AusNet Services (ANV).